Dr. Reddy's Launches Generic Taxotere

Dr. Reddy's Laboratories announced the launch of Docetaxel Injection, the generic version of
Sanofi AventisTaxotere.

Taxotere is an antimicrotubule agent indicated for locally advanced or metastatic breast cancer after failure of prior chemotherapy; in combination with doxorubicin and cyclophosphamide: adjuvant treatment of operable node (+) breast cancer; in combination with cisplatin and fluorouracil: advanced gastric adenocarcinoma without previous chemotherapy; in combination with cisplatin and fluorouracil: induction treatment of locally advanced squamous cell carcinoma of the head and neck; in combination with prednisone: hormone-refractory metastatic prostate cancer; locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy; and in combination with cisplatin: initial treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without previous chemotherapy.

RELATED: Chemotherapy Drug May Cause Alcohol Intoxication

Docetaxel Injection is available in 20mg/mL and 80mg/4mL strengths in single-dose vials.

For more information call (866) 733-3952 or visit DrReddys.com.

Loading links....